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Summary 
Current therapies for prostate cancer include antiandrogens, inhibitory ligands of the 
androgen receptor, which repress androgen-stimulated growth. These include the selective 
androgen receptor modulators cyproterone acetate and hydroxyflutamide and the complete 
antagonist bicalutamide.  Their activity is partly dictated by the presence of androgen 
receptor mutations, which are commonly detected in patients who relapse whilst receiving 
antiandrogens, i.e. in castrate-resistant prostate cancer.  To characterise the early proteomic 
response to these antiandrogens we used the LNCaP prostate cancer cell line, which harbours 
the androgen receptor mutation most commonly detected in castrate-resistant tumours 
(T877A), analysing alterations in the proteome and comparing these to the effect of these 
therapeutics upon androgen receptor activity and cell proliferation.  The majority are 
regulated post-transcriptionally, possibly via non-genomic androgen receptor signalling. 
Differences detected between the exposure groups demonstrate subtle changes in the 
biological response to each specific ligand, suggesting a spectrum of agonistic and 
antagonistic effects dependent on the ligand used. Analysis of the crystal structures of the AR 
in the presence of cyproterone acetate, hydroxyflutamide and DHT identified important 
differences in the orientation of key residues located in the AF-2 and BF-3 protein interaction 
surfaces.  This further implies that whilst there is commonality in the growth responses 
between androgens and those antiandrogens that stimulate growth in the presence of a 
mutation, there may also be influential differences in the growth pathways stimulated by the 
different ligands. This therefore has implications for prostate cancer treatment since tumours 
may respond differently dependent upon which mutation is present and which ligand is 
activating growth, also for the design of selective androgen receptor modulators (SARMs), 
which aim to elicit differential proteomic responses dependent upon cellular context. 
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Introduction 
Prostate tumours are dependent upon the Androgen Receptor (AR) for growth.  The AR is a 
ligand-activated transcription factor that promotes prostate cancer growth through genomic 
and non-genomic actions. In the canonical genomic pathway, the AR regulates transcription 
following interaction with specific DNA sequences, termed androgen response elements, in 
the regulatory regions of target genes (1).  More recently it has been demonstrated that 
cytoplasmic AR, within minutes of activation, also stimulates kinase signalling cascades (e.g. 
ERK and PI3K) and that this non-genomic signalling is also important in proliferation (2). 
The first line of treatment for non-localised therefore inoperable disease is androgen 
blockade.  This involves chemical castration to reduce testicular production of androgens and 
administration of antiandrogens, which bind to the AR and hold it in an inactive state.  
Hormone therapy is initially successful in the majority of patients (3), but invariably 
fails after a median period of 13 months, growth recurs and the disease proceeds to castrate 
resistance (CRPC).   Multiple mechanisms have been proposed to explain castration resistant 
disease and much evidence exists to suggest that even in the androgen-depleted environment, 
the AR continues to drive growth (4).  For example, mutations of the AR have been detected 
in 2-25% of hormone sensitive tumours and 10-40% of cases of hormone refractory disease 
(5). These mutations appear to be the result of selective pressure induced by the treatment 
itself and in some cases the mutant receptors can be activated by alternative ligands, 
including antiandrogens used in therapy (6). The majority of mutations identified to date 
cluster in the ligand binding domain (LBD) of the receptor (4) and of those that have been 
studied at the functional level, several appear to offer a growth advantage due to reduced 
ligand specificity, enhanced androgen sensitivity or constitutive activity (6-10).  Other studies 
have determined the responses of prostate cancer cells to various ligands of the AR and it has 
been demonstrated that ligand-specific gene regulation by the AR can occur (11-13).  
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The most frequently reported mutation, associated with prostate cancer, is a 
substitution of Threonine to Alanine at amino acid 877 (T877A).  The T877A mutation 
appears to be more prevalent in patients who relapse following treatment with the 
antiandrogen hydroxyflutamide (6) and when compared to the wild-type receptor, this mutant 
has increased transcriptional activity in the presence of other steroid hormones, such as 
estradiol and progesterone and also the antiandrogens cyproterone acetate and 
hydroxyflutamide (14). This activation by antiandrogens is not universal, as the antiandrogen 
bicalutamide is able to block activity of this mutant (15).  To determine the extent to which 
proteomic responses to androgens and antiandrogens overlap in the presence of this mutant 
receptor, we exposed the LNCaP prostate cancer cell line, which harbours the T877A AR 
variant, to the dihydrotestosterone (DHT) analogue mibolerone, cyproterone acetate, 
hydroxyflutamide and bicalutamide. 2-dimensional polyacrylamide gel electrophoresis (2-
DE) was used to determine protein regulation in whole cell lysates and sets of regulated 
proteins were compared. Characterisation of the proteomic response to antiandrogen 
exposure will provide further insight into the phenomenon of receptor promiscuity in CRPC 
and also highlight future targets for therapy once antiandrogen resistance has occurred.  
 
Experimental Procedures 
Cell culture and treatments- HeLa cells and the LNCaP prostate cancer cell line were 
obtained from ATCC and cultured at 37ºC, 5% CO2 in Dulbecco’s modified Eagle’s medium 
(DMEM) and Roswell Park Memorial Institute (RPMI) medium 1640 (Life technologies, 
Strathclyde, UK) respectively, both supplemented with 2mM L-Glutamine, 100units/ml 
penicillin, 100mg/ml streptomycin (Sigma Aldrich, St Louis, MO) and 10% foetal bovine 
serum. The LNCaP-PHB cell line has been previously described (16) and was grown in 
media supplemented as above with the exception that 10% tetacycline-free foetal bovine 
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serum was used and the cells additionally supplemented with 12 µg/ml blasticidin 
(Invitrogen, Carlsbad, CA, USA), 500 µg/ml G418 (Sigma-Aldrich) and 0.3 mg/ml zeocin 
(Invitrogen). 
Mibolerone (Perkin-Elmer, Beaconsfield, UK), cyproterone acetate (Sigma-Aldrich, 
Dorsett, UK), bicalutamide (Astra-Zeneca, Cheshire, UK) and hydroxyflutamide (Schering-
Plough, Hertfordshire, UK) were resuspended in ethanol and stored at –20ºC until use, final 
concentrations were 10nM for mibolerone and 1µM for antiandrogens. 
Reporter assays- HeLa cells were grown to 60% confluence in phenol red free media 
containing 5% double charcoal stripped serum, in 24-well plates.  After 24 hours, cells were 
transfected using FuGENE 6 (following the manufacturers instructions) with 100ng wild type 
or mutant pSV-AR, 100ng PDM-LAC-Z-β-GAL and 1µg of luciferase reporter (TAT-GRE-
E1B-LUC) per well.  Eighteen hours post transfection cells were treated with ligand for 24 
hours.  Luciferase and β-galactosidase expression was quantified as previously described 
(14).   
Cell proliferation assay– LNCaP cells were plated at a density of 104 cells per well in 96 well 
plates in RPMI. After 16 hours incubation, the wells were washed twice in phosphate 
buffered saline (PBS) before incubation for 48 hours in phenol-red free RPMI supplemented 
with 5% charcoal stripped FBS, 2mM L-Glutamine, 100units/ml penicillin, and 100mg/ml 
streptomycin.  Hormone was subsequently added to the wells in spent medium from 
concurrently seeded cells and the cells incubated for a further 72 hours. To measure cellular 
proliferation, mitochondrial dehydrogenase activity was assayed using the WST-1 reagent 
(Roche Applied Science Ltd, Hertfordshire, UK) as per manufacturer’s instructions. Eight 
wells were assayed per condition in each of two independent experiments.  
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2-Dimensional Gel Electrophoresis (2-DE)- Five samples were prepared per experimental 
condition. 25cm2 flasks of LNCaP cells were transferred to phenol red-free RPMI 
supplemented with 2mM L-Glutamine, 100units/ml penicillin, 100mg/ml streptomycin and 
10% charcoal stripped foetal bovine serum for 48 hours before exposure to hormone or 
ethanol. Hormone was added to the media and mixed thoroughly. Cells were incubated as 
above for 16 hours, then placed on ice and washed twice in PBS before lysis in 200µl 
isoelectric focussing buffer. Isoelectric focusing (IEF) was performed using immobilized pH 
gradient (IPG) strips (GE Healthcare, Amersham, UK), of pH range 3-10 (linear). The 
solubilised protein sample was applied to the strips during gel rehydration, according to the 
manufacturer‘s instructions. The samples were diluted with rehydration solution containing 
8M urea, 0.5 % CHAPS, 0.2 % DTT and 0.2 % Pharmalyte (pH 3-10) prior to loading, total 
protein loaded was 250 µg in 450 µl. The strips were focused at 0.05 mA/IPG strip for 60 
kVh at 20°C. After IEF, the strips were equilibrated in 1.5M Tris pH 8.8 buffer containing 
6M urea, 30% glycerol, 2% SDS and 0.01% bromophenol blue, with the addition of 1% DTT 
for 15 minutes, followed by the same buffer with the addition of 4.8 % iodoacetamide for 15 
minutes. SDS-PAGE was performed using 12% T, 2.6 % C separating polyacrylamide gels 
without a stacking gel, using the Iso-Dalt system (GE Healthcare). The second-dimension 
separation was carried out overnight at 20 mA/gel, 15°C and was stopped when the 
bromophenol blue dye-front was approximately 1cm from the bottom of the gels.  
 
Protein Spot Imaging and Gel Image Analysis- The dye front on each gel was removed using 
a scalpel blade and the gels fixed in 40% methanol 10% acetic acid for 1 hour. Gels were 
then incubated in Sypro-ruby protein stain (GE Healthcare) overnight then washed in distilled 
water for 30 minutes. Stained gels were scanned using a Typhoon phosphorimager on 
fluorescent mode (GE Healthcare) and analytical images were analysed using PDQuest 
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version 8 (Bio-rad, Hemel Hempstead, UK). After detection of spots, the gels were aligned, 
landmarked and matched. Gels were then placed into the appropriate experimental class and 
differential analysis performed. The student t-test was used to detect all spots that differed 
significantly between the control and exposed groups (p < 0.05), all significantly different 
spots were then checked manually to eliminate any artefactual differences due to gel pattern 
distortions and inappropriately matched or badly detected spots.  
 
Mass spectrometry- Proteins spots of interest were excised manually from gels and subjected 
to in gel digestion with trypsin as described previously (17). Tandem mass spectra were 
recorded using a Q-Tof spectrometer (Waters, Manchester, UK) interfaced to a Waters 
CapLC capillary chromatograph. Samples were dissolved in 0.1% formic acid and injected 
onto a 300 µm x 5 mm Pepmap C18 column (LC Packings, Amsterdam, NL) and eluted with 
an acetonitrile/0.1% formic acid gradient. The capillary voltage was set to 3,500 V. A survey 
scan over the m/z range 400-1300 was used to identify protonated peptides with charge states 
of 2, 3 or 4, which were automatically selected for data-dependent MS/MS analysis, and 
fragmented by collision with argon. The resulting product ion spectra were transformed onto 
a singly charged m/z axis using a maximum entropy method (MaxEnt3, Waters) and proteins 
were identified by correlation of uninterpreted spectra to entries in SwissProt/TrEMBL, using 
ProteinLynx Global Server (Version 2.2, Waters). The database was created by merging the 
FASTA format files of SwissProt (2012_09 release), TrEMBL and their associated splice 
variants (1,768,175 entries at the time of searching). No taxonomic or protein mass and pI 
constraints were applied. One missed cleavage per peptide was allowed, and the initial mass 
tolerance window was set to 100 ppm. For further confirmation of the identifications the 
spectra were also searched against the NCBI nr database (4,496,228 sequences as of January 
2007) using Mascot v.2.2 (www.matrixscience.com)(18). For an identification to be 
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considered valid we required two or more peptides were identified, that the peptide score was 
significant (typically greater than 55 (P<0.05)), and that manual interpretation confirmed 
agreement between spectrum and peptide sequence. In addition Mascot searches of all spectra 
were performed against a randomised version of the NCBI database using the same 
parameters as in the main search. In no case did this search retrieve more than a single 
peptide, and in all instances the peptide score was below the 0.05 significance level.  
 
Immunoblotting. Cells were treated and incubated as indicated, washed in PBS and harvested 
by cell scraping.  Cells were pelleted (1200 rpm, 4 min), lysed in 9M Urea and protein 
concentrations determined using a modified Bradford Assay (19) (Bio-Rad, Hemel 
Hempstead, UK).  SDS PAGE and immunoblotting was performed as described previously 
(20) using the following antibodies: Anti-AR (N-20, Santa Cruz Biotechnology, Dallas, TX, 
USA); Anti-Flag (M-2, Sigma Aldrich) and β-actin (AC-15, Abcam, Cambridge, UK).   
 
Real-time quantitative PCR.  Cells were grown in hormone-depleted media for 72hrs and 
treated with ligand for 16hrs.  RNA was extracted using TRI-Sure reagent (Bioline, Taunton, 
MA, USA) and a DNAse step included (Thermo Scientific, Leicestershire, UK).  Reverse 
transcription was performed using the nanoScript RT Kit (Primer Design, Southampton, UK).  
Alterations in gene expression were quantitifed using a qPCR (Roche LightCycler 96, Roche, 
IN, USA). 
 
Comparison of AR Crystal Structures.   
Crystal structures retrieved from the Protein Data Bank were superposed using a ‘secondary 
structure matching’ algorithm implemented in the program Superpose (21) within the CCP4 
suite (22). Figures were prepared using PyMol (23)  
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Results 
Confirmation of growth and transcriptional responses to androgen and antiandrogens in the 
LNCaP cell line- It is well documented that AR containing the T877A substitution has 
reduced ligand specificity, allowing it to be activated by a range of compounds that repress or 
do not fully activate the wild-type receptor (4). In order to determine the extent of this 
activation for the ligands under investigation, we carried out transcriptional activation assays 
comparing wild-type AR and ART877A in AR negative HeLa cells, and cell growth assays in 
LNCaP cells, in the presence of the synthetic androgen mibolerone (a non-metabolisable 
analogue of the natural ligand DHT, with the same relative binding affinity (24, 25)), the 
partial agonists cyproterone acetate and hydroxyflutamide, and the pure antagonist, 
bicalutamide. The relative binding affinities of the latter 3 ligands for wild-type AR are 
between 1 and 6% as compared to DHT (24, 26) (Supplemental Figure 1).  
 
SUPPLEMENTAL FIGURE 1 
 
Immunoblotting confirmed equal expression of the wild-type and mutant AR in 
transfected cells (Figure 1a). Wild-type AR and ART877A were activated to a similar extent in 
the presence of the higher concentrations of mibolerone (Figure 1b) and in keeping with 
previous studies, ART877A was found to have higher levels of activity when compared to wild-
type AR in the presence of cyproterone acetate and hydroxyflutamide, whereas bicalutamide 
did not activate either of the receptors. To investigate whether this altered transcriptional 
profile correlated with cell growth driven by ART877A, proliferation assays were performed.  
The LNCaP cell line was cultured in the presence of 10nM Mibolerone or 1µM antiandrogen 
for 72 hours. As expected, the growth observed in response to the different ligands correlated 
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with transcriptional response (Figure 1c); mibolerone, cyproterone acetate and 
hydroxyflutamide all induced similar increases in growth that were significantly greater than 
that observed in untreated control cells, whilst no change in growth was evident following 
treatment with bicalutamide.  
 
FIGURE 1 
Regulation of protein features following exposure to androgens and antiandrogens in LNCaP 
cells- The first set of 2-DE experiments was intended to characterise the “pure” androgen- 
and antiandrogen-related responses at the proteome level. Cells were treated with vehicle 
(Ethanol, EtOH), mibolerone or bicalutmide for 16rs.  Five individual protein samples were 
subjected to 2-DE per treatment and between 419 and 997 protein features were detected 
across the gels. Of these features, between 320 and 698 were matched across the data set and 
286 were matched to all 15 gels (Figure 2a). PDQuest analysis detected 34 protein features 
regulated in comparison to ethanol controls, using student T-test with 95% confidence limits, 
with examples of proteins being both up and down regulated and some with multiple 
isoforms being regulated (Table 1 and examples in Figure 2b and c). Of the regulated 
proteins, 12 were regulated only by mibolerone, 17 by bicalutamide, and 5 were regulated by 
both (Figure 2d).  
 
FIGURE 2 
We next determined the extent to which exposure of the LNCaP cells to the partial 
agonists cyproterone acetate and hydroxyflutamide correlated with the responses to pure 
androgen or antiandrogen observed in the first experiment. Again 5 protein samples were 
processed per condition (vehicle, mibolerone, cyproterone acetate and hydroxyflutamide). 
The 2D gels contained between 360 and 589 protein features, and in total 241 features were 
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matched across all gels (Figure 3a). PDQuest analysis detected 38 protein features regulated 
in comparison to ethanol controls, using student T-test with 95% confidence limits (Figure 3b 
and c). Of these, 15 were regulated by mibolerone, 25 by cyproterone acetate and 17 by 
hydroxyflutamide (Figure 3d and Table 1). Overlap between groups was greatest for features 
regulated by both hydroxyflutamide and cyproterone acetate, with 12 proteins being 
commonly regulated. Five proteins were commonly regulated between cyproterone acetate 
and mibolerone treated cells, whilst 3 were regulated in common between hydroxyflutamide 
and mibolerone. Only 1 protein feature was shown to be commonly regulated between all 
three exposure groups. 
 
FIGURE 3 
Protein identities of regulated features- Mass spectrometry of regulated protein features 
resulted in identification of a total of 37 proteins, excluding hits where fewer than two 
peptides were positively identified (Table 1). Proteins were submitted to Gene Ontology 
analysis (Scaffold) to identify key processes/functions regulated by the AR pathway.  Similar 
to previous studies (e.g. (27)) the largest ontology grouping found to be regulated by the AR 
was Metabolic Processing (Figure 4). 
 
FIGURE 4 
Proteins regulated by mibolerone were associated with a wide spectrum of functions 
and pathways, including cell cycle regulation (e.g. prohibitin), protein folding (e.g. protein 
disulphide isomerise 6), ATP synthesis (e.g. ATP-synthase alpha chain) and gene 
transcription (e.g. Protein DJ-1). Proteins regulated in common between mibolerone and the 
antiandrogens were included in many of these same pathways and included the antioxidant 
defence enzymes catalase and peroxidoredoxin 2 (Table 1). Generally, proteins down 
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regulated by bicalutamide tended to be involved in metabolic or protein synthesis pathways 
(e.g. lactoglutathione lyase and Methylmalonate-semialdehyde dehydrogenase) or antioxidant 
defence (e.g. peroxidoredoxin 4). 
TABLE 1 
 
The AR targets are predominantly regulated at the post-transcriptional level. To investigate 
whether the target proteins are regulated at the transcriptional level, LNCaP cells were treated 
with ligand for 16hrs, RNA harvested and qPCR performed for a selection of the protein-
encoding genes identified.  As a positive control, we confirmed mibolerone, cyrpoterone 
acetate and hydroxyflutamide induction of the known AR target kallikrein 2 (KLK2).  No 
significant change in expression was evident for the targets, with the exception of glutamate 
dehydrogenase (GLUD1), which was found to be up-regulated 3-fold in response to 
mibolerone.  It therefore appears that the majority of alterations in the proteome in response 
to androgen receptor activation/inhibition, at this early time-point, are at the post-
transcriptional level. 
 FIGURE 5 
The androgen down-regulated target prohibitin: a suppressor of cell growth.  Androgen 
signalling is a key driver of prostate cancer growth and as such, factors regulated by the AR 
are likely to be important in proliferation.  An example of this is Prohibitin (PHB), which we 
have demonstrated to be androgen-regulated and to regulate LNCaP proliferation (data herein 
and (28)).  PHB was found to be down-regulated in response to androgen, with little change 
evident in response to cyproterone acetate, hydroxyflutamide or bicalutamide (Figure 5a).  
We were interested to see if PHB could block LNCaP growth activated not only by androgen 
but also by cyproterone acetate and hydroxyflutamide.  To perform this experiment, we 
utilised the LNCaP cell line stably transfected with the PHB gene under the control of the 
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doxycycline promoter (29).  Cells were plated in hormone-depleted media and treated with 
concentration ranges of mibolerone, bicalutamide, hydroxyflutamide or cyproterone acetate ± 
doxycycline and proliferation assessed after 4 days.  As expected, increasing concentrations 
of mibolerone, cyproterone acetate and hydroxyflutamide promoted cell growth (Figure 6b-
d), whereas bicalutamide had no effect on proliferation (Figure 6e).  Over-expression of PHB 
was found to significantly block the growth promoting effects of mibolerone with no 
significant increase in growth evident at any concentration of mibolerone (ANOVA, p>0.05).  
In contrast, PHB was less efficient at inhibiting the growth promoting effects of 
hydroxyflutamide and cyproterone acetate (41% and 67% inhibition of AR activity 
respectively, compared to 94% in presence of MIB) suggesting that the inhibitory effects of 
PHB are dependent upon the ligand driving growth (Figure 6c-d). 
 
FIGURE 6 
 
The different ligands are associated with different conformations in the AR AF-2 and BF-3 
interaction domains.  To investigate potential mechanisms by which ART877A promotes 
ligand-dependent alterations in the proteome of LNCaP cells, we undertook detailed analysis 
of the available crystal structures of the ART877A ligand-binding domain in the presence of 
DHT (PDB accession number 1i38), cyproterone acetate (2oz7) or hydroxyflutamide (2ax6).  
The AF-2 and BF-3 regions of the AR are known interaction sites for co-factors and hence 
our analysis focussed on these regions (Figure 7a) (30-32) 
The AF-2 surface of the AR ligand-binding domain consists of a hydrophobic cleft 
with charged clamp residues (Lys 720 and Glu 897) positioned at either end of the groove 
(14, 33).  Alpha-helical motifs found in coactivators bind to this groove and form interactions 
with the highlighted residues (Figure 7b) (30, 34).  The majority of residues within the AF-2 
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region are similar in position in all three structures (Figure 7b and c). However, the side chain 
positions of residues Met734, Asp731 and Met894 are similar for cyproterone acetate and 
hydroxyflutamide, but differ to that evident for the DHT complex.  The shift in the Met894 
position in the DHT complex in particular results in the side chain aligning within the groove, 
significantly reducing its size. The charge clamp residue Glu897 exhibits significant 
variability, with a different orientation in the hydroxyflutamide complex compared to that in 
the other two structures.  
The BF3 domain of the AR is an allosteric pocket that has also been demonstrated to 
be important in receptor function and protein interactions (30, 32).   In the case of the BF3 
domain, fewer differences are apparent between the three structures although the side chain 
of Glu 829 occupies a different rotamer in the DHT complex compared to the other 
structures, with Arg 840 being differently positioned in all structures (Figure 7c).  In 
summary, the conformation of the AF-2 and BF-3 surfaces are most similar when the 
receptor is in complex with SARMs cyproterone acetate and hydroxyflutamide, however 
differences in conformation are apparent for all ligands investigated. 
 
FIGURE 7 
 
Discussion 
Resistance of prostate cancer to hormone therapy is a common occurrence in patients 
exposed to long-term treatment. Multiple mechanisms have been proposed to explain therapy 
relapse, including mutation of the AR resulting in constitutively or promiscuously active 
receptor. The reported frequency of AR mutation in recurrent prostate cancer varies greatly 
between studies, ranging from 10-50%, but incidence does appear to correlate with therapy 
resistance (4, 5, 35).  One mutation detected in the AR of prostate cancer patients is a 
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substitution of threonine to alanine at amino acid 877 (6), which is also present in the LNCaP 
prostate cancer cell line. In this study, we investigated the proteomic response of the LNCaP 
cell line in response to an androgen, the activating antiandrogens cyproterone acetate and 
hydroxyflutamide, and bicalutamide, which remains antagonistic to LNCaP growth (36). The 
synthetic DHT analogue mibolerone was used throughout the study since DHT is rapidly 
metabolised and inactivated in LNCaP cells (37); studies using androgen analogues have 
shown a high degree of overlap with DHT response demonstrating that the action of these 
synthetic ligands is comparable with the natural ligand  (38). 
The ART777A variant is known to be activated by several antiandrogens, including 
cyproterone acetate and hydroxyflutamide, and thus we have used it to determine the early 
proteomic responses to such ligands versus the response to androgen. Using WST1 
proliferation assays (succinate dehydrogenase activity as a surrogate for proliferation) we 
confirmed that mibolerone and the antiandrogens cyproterone acetate and hydroxyflutamide 
promote growth of LNCaP cells.  We note that our proteomic results demonstrated that the 
AR regulates a number of proteins involved in metabolism, however, the expression of 
succinate dehydrogenase was not found to be regulated in response to any of the ligands 
tested and our WST1 results correlate with similar proliferation studies that have utilised 
alternative methods to assess cell growth (e.g. (15, 39) ) 
 This study has demonstrated that different ligands largely regulate different subsets of 
proteins, although some degree of overlap was detected between the two partial agonists and 
mibolerone.  Interestingly, more than half of the mibolerone-regulated proteins identified 
here have been previously shown to be androgen regulated in proteomic studies of the 
LNCaP cell line (12, 27, 40, 41). (Of note, our study identified fewer androgen target proteins 
than these previous studies, which may be explained by the shorter treatment time (16 hours 
as opposed to 48-72 hours) resulting in fewer indirect androgen protein targets being 
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significantly regulated.)  In contrast, 80% of proteins regulated by cyproterone acetate and/or 
hydroxyflutamide, were not identified in these previous studies, supporting the supposition 
that these ligands promote an alternative proteomic response compared to the cognate ligand. 
The overlapping responses between androgen and the activating anti-androgens are of 
particular importance because they may therefore represent truly agonistic responses of the 
liganded receptor. Unsurprisingly, the largest differences were detected between cells 
exposed to the agonist mibolerone and the pure antiandrogen, bicalutamide. Following 
bicalutamide treatment, the majority of responsive proteins were down-regulated. These 
included proteins involved in protein synthesis, glycolysis and cell signalling, such as 
lactoglutathione lyase and Ran specific GTPase activating protein. Exceptions to this 
observation included 75kDa heat shock protein (HSP75), also known as TRAP1 (tumor 
necrosis factor receptor-associated protein-1), which was up-regulated by bicalutamide.  
TRAP1 has antiapoptotic functions and plays a role in multidrug resistance in colorectal 
carcinoma (42).  The up-regulation of TRAP1 in response to bicalutamide may therefore be a 
cellular stress response induced by the antiandrogen.  
Far upstream element-binding protein 2 (FBP2) was up-regulated in the presence of 
all of the antiandrogens tested, suggesting that this protein is regulated as part of an inhibitory 
response. The strongest response was to the pure antagonist bicalutamide, whilst an 
intermediate response was observed in the presence of the partial agonists hydroxyflutamide 
and cyproterone acetate. FBP2 is involved in AU-rich element (ARE)-mediated decay of 
mRNA species.  This post-transcriptional regulation is important in physiological cellular 
proliferation and is a process that has been found to be de-regulated in cancer (43).  
Additionally, EF2 was regulated by all the various treatments used. Functioning as a protein 
elongation factor, EF2 is regulated by a specific kinase EF2K, which is under the regulation 
of mTOR (44), indicating that the mTOR pathway is a point of commonality in all AR 
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responses and therefore may have an important role in androgen regulated cell growth. The 
EF2 protein is inactivated by phosphorylation, and inactivation of EF2K is increased by 
mTOR activity in breast cancer cells (45). Other groups have shown that upregulation of 
mTOR activity occurs following androgen stimulation of LNCaP cells and in androgen 
independent variants of the LNCaP cell line (46-48). Our data identified regulation of two 
EEF2 isoforms, one of which was up-regulated in cyproterone acetate and hydroxyflutamide 
exposed cells, whilst the second was up-regulated in the presence of all treatments. It may 
therefore be the case that EEF2 levels were generally up-regulated in response to treatment, 
indicating a need for increased translation in all exposed cells irrespective of the nature of the 
treatment, whereas the modification may be a specific response to certain ligands via mTOR 
regulation of EEF2 kinase.  
Our 2D gels showed two close lying spots, each significantly down-regulated, one by 
mibolerone, the other by cyproterone acetate and hydroxyflutamide, which were both 
identified as DJ-1. DJ-1 has been previously shown to increase AR activity by abrogating 
binding of the inhibitory histone deacetylase (HDAC) complex (49) and expression is 
upregulated in several cancers, including prostate cancer (50, 51).  The differential regulation 
of isoforms of DJ-1 by pure agonist versus partial agonist again suggests that there is not total 
overlap between the responses to the various ligands used.  A previous study of DJ-1 in 
LNCaP cells found that protein, but not mRNA levels were increased after 48hrs of treatment 
with mibolerone and hydroxyflutamide (52). We also found no change in the mRNA levels 
following treatments.  This observation confirms the importance of data obtained at the 
proteomic level which would not be apparent from transcript based studies and suggests that 
in addition to regulation of total protein levels, regulation of the isoforms of DJ-1 occurs, 
perhaps by post-translational modification.  Of the 10 targets investigated by qPCR, only 
GLUD1 was regulated at the transcriptional level.  This therefore suggests that the majority 
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of early targets identified in this study are regulated by the non-genomic action of the AR.  
Non-genomic AR signalling is known to occur within minutes of activation and is mediated 
by the cytoplasmic AR, which activates kinase signalling cascades such as mTOR and PI3K 
(2)   
The ability of steroid receptors to accept a variety of steroidal and non-steroidal 
compounds as ligands is not unique to the AR. The transcriptional response of estrogen 
receptor α when stimulated by a range of alternative ligands has been investigated (53).  
Synthetic ligands for the estrogen receptor exhibit tissue specific agonist- or antagonist-like 
activities, and are thus termed “selective estrogen receptor modulators” (SERMs) (54, 55). 
Further, microarray studies of estrogen receptor α-mediated gene expression have 
demonstrated a spectrum of responses following exposure to estradiol, the SERMs tamoxifen 
and raloxifene and the pure antiestrogen ICI 182,780 (53). Our data indicates that this may 
also be true at the protein level for ART877A. Each ligand promotes regulation of a specific set 
of proteins, which overlap to incorporate the proteins commonly regulated between various 
ligands. Frequently the magnitude of response for each protein was found to vary according 
to ligand and several of the proteins regulated by one ligand also showed regulation by the 
others, although not to a statistically significant degree.   
In terms of mechanism, the difference in the level of response is likely due to the 
range of possible conformational changes in the receptor structure when bound to the 
different ligands.  Analysis of available crystal structures of the ART877A ligand binding 
domain in complex with DHT, cyproterone acetate or hydroxyflutamide identified important 
differences in the orientation of residue side chains that form the AF-2 and BF3 domains.  In 
agreement with the finding that the antiandrogens cyproterone acetate and hydroxyflutamide 
had the greatest proteomic overlap, generally the conformation of the AF-2 and BF3 surfaces 
induced by these ligands was also similar and differed to that induced by DHT.  
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The BF3 domain of the AR is an allosteric pocket that has recently been demonstrated 
to be the site of interaction for the cochaperone Bag-1L and has received much interest as a 
novel site for therapeutic targeting (30, 32, 56).   The AF-2 coactivator interaction groove 
consists of a hydrophobic cleft with charge-clamp residues (Lys720 and  Glu897) situated at 
either end (14, 33).  Coactivator interaction motifs can be broadly separated into two 
categories: LxxLL-type motifs and FxxLF-type motifs (where x=any amino acid).  The AR 
preferentially interacts with the latter, since phenylalanine-rich motifs form electrostatic 
interactions with both charge-clamp residues whereas leucine-rich motifs only form hydrogen 
bonds with Lys720 (57).  Since Glu897 is located on helix 12, which acts as a lid to the 
ligand-binding pocket, the positioning of this residue is greatly dependent upon the ligand 
bound.  Indeed, the crystal structure analysis demonstrated that this residue adopts a different 
conformation for each of the ligands investigated. The AF-2 residues Met734, Asp731 and 
Met894 are also known to be important in coactivator interaction motif binding.  The 
orientation of these was similar in the cyproterone acetate and hydroxyflutamide complexes 
and differed to that induced by DHT. Such conformational changes likely in turn affect 
protein-protein interactions with accessory proteins. We therefore hypothesise that the 
differences in protein expression identified here are as a result of ligand-specific receptor 
conformations, which promote different complex formations, subsequently affecting target 
regulation.  
 It follows that a mutant receptor activated by an antiandrogen may not elicit the same 
cellular responses as a wild type receptor activated by androgen. This implies that, in prostate 
cancer, recurrent tumours with a mutant receptor may behave differently depending on the 
mutation present and the ligands available to stimulate growth.  Supporting evidence for this 
comes from our studies of the putative tumour suppressor prohibitin.  In the presence of 
mibolerone, prohibitin is down-regulated. This suggests that loss of prohibitin is important in 
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androgen-induced growth, in accordance with our previous data (29). Cyproterone acetate 
and hydroxyflutamide only weakly reduced prohibitin levels and hence we believe that loss 
of prohibitin is less important for growth induced by these ligands. In support of this, 
exogenous expression of prohibitin was significantly more potent at inhibiting androgen-
induced growth compared to cyproterone acetate/hydroxyflutamide-induced growth.  
Recently, second generation antiandrogens, such as ARN-509 and Enzalutamide, have 
entered the clinic or trials (58).   This study is also likely to have relevance to these 
antiandrogens since AR mutations have also been associated with resistance to these 
therapies.  For example, the AR mutation resulting in F876L has been associated with ARN-
509 and Enzalutamide failure and identified in the plasma of CRPC patients (59, 60). We 
therefore conclude that the AR promotes differential changes in the proteome dependent upon 
the activating ligand and/or the mutation present and these changes appear to have a bearing 
on growth. 
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Figure Legends 
Figure 1. Effect of T877A substitution on AR activity and cell growth in the presence of 
androgens and antiandrogens. a, Expression levels of the transfected wild-type and T877A 
mutant androgen receptors. Cells were transfected with expression vector for either the wild-
type AR or ART877A and a flag-tagged control plasmid (to control for transfection efficiency).  
The empty lane refers to cells transfected with empty plasmid.  Cells were lysed and proteins 
visualised by Western blotting.  Blots were probed with anti-AR and re-probed with anti-flag 
and β-actin antibodies. b, HeLa cells were transiently transfected with expression vector for 
either the wild-type AR or ART877A mutant, TAT-GRE-E1B-LUC luciferase reporter and a β-
galactosidase expression vector. Cells were exposed to ligand for 16 hours.  Luciferase 
activities were normalized for β-galactosidase activity and expressed as a percentage of the 
wild-type receptor activity in the presence of 10-7 M MIB.  Data presented are the mean of 3 
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independent experiments performed in duplicate ± S.D.. c, LNCaP cells were exposed to 
10nM mibolerone, or 1µM antiandrogen, for 72 hours and proliferation measured using 
WST-1 assays. Representative data of 3 individual experiments is presented, bars are means 
+ S.D. of 8 replicates. ANOVA + Tukey: * P<0.05, ** P<0.005, *** P<0.001. Significant 
differences are comparison between AR wild-type and AR T877A in b, and between EtOH 
and ligands in c,.  ETOH, ethanol; MIB, mibolerone; CPA, cyproterone acetate; OHF, 
hydroxyflutamide; BIC, bicalutamide. 
 
Figure 2. 2-DE profile of cell extract from LNCaP exposed to mibolerone and bicalutamide.  
LNCaP cells in culture were exposed to 10nM mibolerone, or 1µM antiandrogen, for 16 
hours. a, Filtered, inverted, fluorescent gel image of gel used as master gel. Cell lysates were 
subjected to IEF over a linear range of pI 3-10 and 12% PAGE on 24cm gels. Differential 
regulation of protein features was detected using PDQuest software using student t-test 
(P<0.05). b, regulation of protein features by exposure to androgen and anti-androgen. 
Images are filtered inverted fluorescent gel images of individual gels; regulated protein 
features are highlighted with arrows. c, graphical representation of regulated protein features. 
Data shown represents mean + S.D. of fluorescence intensity recorded for each gel, n=5 
(samples from independent studies). d, Venn diagram of numbers of regulated protein 
features. ETOH, ethanol; MIB, mibolerone; BIC, bicalutamide. T-Test: *** p<0.001. 
Significant differences are comparison between EtOH and other ligands. 
 
Figure 3. 2-DE profile of cell extract from LNCaP exposed to mibolerone and anti-
androgens.  LNCaP cells in culture were exposed to 10nM mibolerone, or 1µM antiandrogen, 
for 16 hours. a, Filtered, inverted, fluorescent gel image of gel used as master gel. Cell lysates 
were subjected to IEF over a linear range of pI 3-10 and 12% PAGE on 24cm gels. 
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Differential regulation of protein features was detected with PDQuest software using student 
t-test (P<0.05). b, regulation of protein features by exposure to androgen and anti-androgen. 
Images are Gaussian, inverted, fluorescent, gel images of individual gels; regulated protein 
features are highlighted with arrows.  c, graphical representation of regulated protein features. 
Data shown represents mean + S.D. of fluorescence intensity recorded for each gel, n=5 
(samples from independent studies). d, Venn diagram of numbers of regulated protein 
features. ETOH, ethanol; MIB, mibolerone; CPA, cyproterone acetate; OHF, 
hydroxyflutamide. T-Test: * p<0.05, **p<0.005, *** p<0.001. Significant differences are 
comparison of EtOH and other ligands. 
 
 
Figure 4. Gene Ontology analysis of proteins regulated by the androgen receptor.  Biological 
Processes were assigned using Scaffold Viewer (Proteome Software). 
 
Figure 5.  The AR target proteins are predominantly regulated at the post-transcriptional 
level.  LNCaP cells were grown in steroid-depleted media for 72hrs and treated with ligand 
for 16hrs.  RNA was harvested, reverse transcriped and qPCR performed to investigate 
alterations in relative gene expression.  Gene expression was normalized to L19 expression.  
Mean of 4 repeats ± 1sd. T-Test * p<0.05. 
 
Figure 6. Prohibitin selectively blocks androgen induced prostate cancer growth.  (a) LNCaP 
cells were grown in hormone-depleted medium for 48 hrs and treated with 10nM mibolerone 
or 1µM antiandrogen, or equivalent volume of ethanol for 16 hours.  Protein lysates were 
separated by Western blotting and visualised using immunodetection and densitometry 
performed (mean of 3 independent repeats ± 1 S.D.). T-Test *p<0.05.  (b-d)  the LNCaP-PHB 
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cell line was grown in hormone-depleted medium for 72hrs, treated with ligand for 96hrs and 
proliferation assessed using WST1 assays. Mean of 3 independent replicates ± 1 S.D.. 
ANOVA * p<0.05, ** p<0.005, *** p<0.001. Significant differences are comparison of 
EtOH and other ligands in a, and comparison of – and + DOX in b-e. 
 
Figure 7: The ligands promote different conformations in the AF-2 and BF-3 surfaces of the 
AR ligand binding domain.  (A) Surface representation of AR T877A ([4], PDB accession 
number 1I38) with the AF-2 and BF-3 regions coloured orange and purple respectively; (B) 
the AF-2 region in the superposed structures of the androgen receptor T877A variant in 
complex with DHT ([4], 1I38, red), cyproterone acetate ([5], 2oz7, blue) and 
hydroxyflutamide ([6], 2ax6, green). (C) the same superposition showing residues in the BF-
3 region (61-63).  
 
Table 1. LNCaP cells in culture were exposed to 10nM mibolerone, 1µM antiandrogen, or 
equivalent volume of ethanol for 16 hours. Protein lysates were subjected to 2-DE as 
described under “Experimental Procedures” and expression profiles compared to the ethanol 
control gels. The identities of individual protein spots were identified by mass spectrometry, 
excluding identities where fewer than two peptides were matched. MIB, mibolerone; CPA, 
cyproterone acetate; OHF, hydroxyflutamide; BIC, bicalutamide. *, This isoform of protein 
DJ1 was included due to an acceptably high MASCOT score on the single peptide identified 
and the conclusive identification of the adjacent isoform. The spectrum for this peptide is 
given in Supplemental Figure 2. 
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Table 1 
 
Proteins regulated by androgen and antiandrogens in the LNCaP prostate cancer cell line 
 
 
Protein UniProtKB 
/Swiss-Prot  
Unique 
Peptides 
identified 
Mass 
(Da) 
pI % 
coverag
e 
Regulation  Peptide Sequences Actual 
mass 
Parent 
charge 
Delta 
AMU 
Mascot 
Identity 
Score 
Previous 
proteomic 
studies 
Regulation by one ligand             
Regulation by mibolerone             
Fructose-bisphosphate aldolase A, 
ALDOA 
P04075 2 39421 8.5 7 ↑ MIB (K)ADDGRPFPQVIK(S) 
(K)GILAADESTGSIAK(R) 
 
1,341.73 
1,331.71 
3 
2 
0.0289 
0.0176 
43.7038 
43.9277 
 
Glyceraldehyde-3-phosphate 
dehydrogenase, GAPDH 
P04406 4 36053 8.7 19 ↑ MIB (R)GALQNIIPASTGAAK(A) 
(K)LVINGNPITIFQER(D) 
(K)VIHDNFGIVEGLMTTVHAITATQK(T) 
(R)VVDLMAHMASKE(-)  
 
1410.79 
1612.89 
2610.37 
1361.64 
2 
2 
4 
2 
0.0042 
-0.0030 
0.0214 
0.0097 
43.3937 
43.4891 
42.0445 
43.6173 
Up with 
androgen 
(24)  
Protein disulphide isomerase, P4HB P07237 4 57118 5.0 17 ↑ MIB (K)MDSTANEVEAVK(V) 
(R)NNFEGEVTKENLLDFIK(H) 
(R)TGPAATTLPDGAAAESLVESSEVAVIGFFK(D) 
(K)VDATEESDLAQQYGVR(G) 
 
1,308.60 
2,009.02 
2,934.46 
1,779.83 
2 
3 
3 
2 
0.0089 
0.0104 
-0.0220 
0.0014 
43.2936 
42.8724 
41.5042 
43.2064 
Up with 
androgen 
(11)  
ATP synthase alpha chain, ATP5A1 P25705 8 59752 9.4 21 ↓ MIB  (R)EVAAFAQFGSDLDAATQQLLSR(G) 
(R)ILGADTSVDLEETGR(V) 
(K)LKEIVTNFLAGFEA(-) 
(K)QGQYSPmAIEEQVAVIYAGVR(G) 
(R)TGAIVDVPVGEELLGR(V) 
(R)TGAIVDVPVGEELLGRVVDALGNAIDGKGPIGSK(A) 
(K)TSIAIDTIINQK(R) 
(R)VVDALGNAIDGKGPIGSK(A) 
 
2,337.15 
1,574.79 
1,550.83 
2,324.14 
1,623.88 
3,315.82 
1,315.74 
1,709.46 
3 
2 
2 
2 
2 
4 
2 
3 
-0.0075 
0.0102 
-0.0007 
-0.0077 
0.0006 
0.0108 
0.0075 
-0.4724 
42.6079 
43.6403 
43.3614 
42.5195 
43.2758 
40.8962 
44.0358 
46.1755 
 
Prohibitin, PHB P35232 6 29805 5.7 36 ↓ MIB (K)AAELIANSLATAGDGLIELR(K) 
(K)AAIISAEGDSK(A) 
(K)FGLALAVAGGVVNSALYNVDAGHR(A) 
(R)FVVEKAEQQKK(A) 
(K)KAAIISAEGDSK(A) 
(R)VLPSITTEILK(S) 
1,996.68 
1,060.56 
2,370.25 
1,332.76 
1,188.66 
1,212.47 
2 
2 
3 
2 
2 
2 
 
-0.40030 
0.01648 
0.00730 
0.01518 
0.02428 
-0.26790 
45.7758 
44.3077 
42.4301 
43.7535 
44.0912 
45.2466 
Down with 
androgen  
(11)  
Transketolase, TKT P29401 6 67879 7.6 15 ↓ MIB (K)ILATPPQEDAPSVDIANIR(M) 
(R)MPSLPSYK(V) 
(K)NMAEQIIQEIYSQIQSK(K) 
(K)NSTFSEIFKK(E) 
(R)SVPTSTVFYPSDGVATEK(A) 
2,018.85 
937.384 
2,037.82 
1,199.51 
1,883.74 
2 
2 
3 
2 
2 
-0.2093 
-0.07394 
-0.1855 
-0.1114 
-0.1749 
44.2177 
42.8301 
44.7493 
44.5603 
45.1061 
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(R)VLDPFTIKPLDR(K)  
 
1,412.70 2 -0.1078 43.9023 
Protein DJ-1, PARK7 Q99497 5 19891 6.5 40 ↓ MIB 
 
(K)DGLILTSR(G) 
(K)EGPYDVVVLPGGNLGAQNLSESAAVK(E) 
(K)GAEEmETVIPVDVmRR(A) 
(R)GPGTSFEFALAIVEALNGK(E) 
 
873.33 
2583.32 
1862.43 
1920.01 
 
2 
3 
3 
2 
 
-0.1643 
-0.0026 
-0.4600 
0.0130 
 
45.5546 
42.1269 
46.1251 
42.9763 
  
Up with 
androgen 
(11)  
 
Regulation by partially activating 
anti-androgens 
           
Electron transfer flavoprotein subunit 
alpha, ETFA 
P13804 10 35080 8.8 45 ↑ CPA (K)DPEAPIFQVADYGIVADLFK(V) 
(K)GLLPEELTPLILATQK(Q) 
(R)GTSFDAAATSGGSASSEK(A) 
(K)IVAPELYIAVGISGAIQHLAGMK(D) 
(K)LLYDLADQLHAAVGASR(A) 
(K)SDRPELTGAK(V) 
(K)SGENFKLLYDLADQLHAAVGASR(A) 
(K)SPDTFVR(T) 
(K)TIVAINKDPEAPIFQVADYGIVADLFK(V) 
(R)VAAKLEVAPISDIIAIK(S) 
 
2,207.12 
1,734.98 
1,629.71 
2,366.30 
1,811.97 
1,072.57 
2,474.27 
820.433 
2,946.57 
1,750.08 
2 
2 
2 
3 
3 
2 
4 
2 
3 
3 
0.0039 
-0.0303 
0.0030 
-0.0069 
0.0157 
0.0156 
0.0121 
0.0251 
-0.0004 
0.0170 
42.6515 
43.2673 
43.3319 
42.5188 
43.1861 
44.5317 
42.2274 
44.0125 
41.5116 
42.6259 
Up with 
androgen 
(24)  
Heterogeneous nuclear 
ribonucleoprotein A2, HNRNPA2 
P22626 2 37430 9.1 9 ↑ CPA (R)GFGFVTFDDHDPVDKIVLQK(Y) 
(K)YHTINGHNAEVR(K)  
2,276.15 
1,409.70 
3 
3 
-0.0019 
0.0234 
 
42.4561 
43.4488 
 
Heterogeneous nuclear 
ribonucleoprotein L, hnRNP L 
P14866 4 64132 7.1 7 ↑ CPA (K)ISRPGDSDDSR(S) 
(K)SKPGAAMVEMADGYAVDR(A) 
(K)SKPGAAMVEMADGYAVDR(A) 
(R)VFNVFCLYGNVEK(V) 
 
1,203.56 
1,898.87 
1,898.86 
1,587.79 
2 
3 
3 
2 
0.0131 
0.0201 
0.0084 
0.0099 
43.9155 
43.0884 
43.0820 
43.5862 
Down with 
androgen  
(32) 
Succinyl-COa:3-ketoacid-coenzyme 
A transferase 1, OXCT1 
P55809 5 56159 7.6 14 ↓ CPA (K)AVFDVDKKK(G) 
(K)DGSVAIASKPR(E) 
(K)GLTAVSNNAGVDNFGLGLLLR(S) 
(K)GMGGAMDLVSSAK(T) 
(R)QYLSGELEVELTPQGTLAER(I) 
 
1,048.61 
1,099.61 
2,100.10 
1,254.57 
2,232.12 
2 
2 
2 
2 
2 
0.0178 
0.0066 
-0.0323 
0.0103 
-0.0080 
43.8419 
44.1472 
42.7747 
43.3927 
42.7107 
 
             
Regulation by bicalutamide             
RuvB-like 2, RUVBL2 Q9Y230 3 51158 5.6 10 ↑ BIC (R)AVLIAGQPGTGK(T) 
(K)EYQDAFLFNELK(G) 
(R)TQGFLALFSGDTGEIKSEVR(E) 
1,110.65 
1,515.75 
2,154.11 
2 
2 
3 
0.0135 
0.0216 
0.0118 
 
42.8538 
43.6769 
42.7224 
 
Heat Shock Protein 75kDa, HSP75 Q12931 4 80113 8.0 11 ↑ BIC (R)GVVDSEDIPLNLSR(E) 
(R)SIFYVPDMKPSMFDVSR(E) 
(R)YESSALPSGQLTSLSEYASR(M) 
(K)YSNFVSFPLYLNGR(R) 
 
1,512.66 
2,049.75 
2,144.85 
1,675.68 
2 
3 
2 
2 
  
-0.1235 
-0.1992 
-0.1695 
-0.1535 
  
44.4245 
45.4958 
45.0706 
44.9867 
 
Glutathione S-transferase Mu 3, 
GSTM3 
P21266 2 26561 5.4 15 ↓ BIC (K)FKLDLDFPNLPYLLDGK(N) 
(K)LTFVDFLTYDILDQNR(I) 
 
2,007.09 
1,972.02 
3 
2 
0.0170 
0.0216 
42.9383 
42.8312 
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Lactoglutathione lyase, GLO1 Q04760 4 20779 5.3 27 ↓ BIC (K)DFLLQQTMLR(V) 
(R)FEELGVK(F) 
(K)FSLYFLAYEDKNDIPK(E) 
(R)VLGMTLIQK(C) 
1,279.54 
820.37 
1,961.85 
1,017.49 
 
2 
2 
2 
2 
  
-0.1168 
-0.0599 
-0.1308 
-0.0992  
43.8582 
44.0207 
44.0524 
44.4769 
 
Methylmalonate-semialdehyde 
dehydrogenase, ALDH6A1 
Q02252 2 57840 8.5 5 ↓ BIC (K)AISFVGSNK(A) 
(R)VNAGDQPGADLGPLITPQAK(E) 
921.41 
1960.88 
2 
2 
 
-0.0779 
-0.1390 
43.3670 
43.3905 
 
ATP synthase subunit beta, ATP5B P06576 3     56561 5.3 12 ↓ BIC (R)AIAELGIYPAVDPLDSTSR(I) 
(K)SLQDIIAILGmDELSEEDKLTVSR(A) 
(K)VLDSGAPIKIPVGPETLGR(I) 
(K)VLDSGAPIKIPVGPETLGR(I)  
 
1,987.07 
2,690.39 
1,918.10 
1,918.13 
2 
3 
3 
3 
0.0412 
0.0168 
0.0095 
0.0452 
42.9732 
41.9413 
43.5095 
43.9718 
 
Peroxiredoxin 4, PDX4 Q13162 2 30541 6.2 8 ↓ BIC (R)IPLLSDLTHQISK(D) 
(R)LVQAFQYTDK(H)  
1,463.89 
1,211.64  
 
3 
2 
 
0.0504 
0.0169 
43.1435 
43.4573 
 
Ran-specific GTPase-activating 
protein, RANBP1 
P43487 2 23311 5.3 10 ↓ BIC (R)FLNAENAQK(F) 
(K)TLEEDEEELFK(M) 
 
1,033.44 
1,380.53 
2 
2 
-0.0796 
-0.1010 
44.4553 
44.8707 
 
             
Regulation by multiple ligands             
Regulation by antiandrogens only             
ATP-dependent RNA helicase, 
DDX3X 
O00571 7 73246 7.2 15 ↑ CPA>↑ 
OHF 
(K)DLLDLLVEAK(Q) 
(R)LEQELFSGGNTGINFEK(Y) 
(R)QSSGASSSSFSSSR(A) 
(K)QYPISLVLAPTR(E) 
(R)SFLLDLLNATGKDSLTLVFVETK(K) 
(K)SPILVATAVAAR(G) 
(R)VGSTSENITQK(V)  
 
1,127.65 
1,881.91 
1,360.59 
1,356.78 
2,523.38 
1,167.71 
1,162.59 
2 
2 
2 
2 
3 
2 
2 
0.0058 
0.0016 
0.0044 
0.0068 
-0.0065 
0.0157 
0.0084 
43.9529 
42.9234 
43.6023 
43.6832 
42.1569 
42.6834 
43.8810 
 
Far upstream element-binding protein 
2, FBP-2  
Q92945 5 73116 8.3 11 ↑ BIC, 
CPA, OHF 
(K)AINQQTGAFVEISR(Q) 
(K)IGGDAATTVNNSTPDFGFGGQKR(Q) 
(R)IINDLLQSLR(S) 
(R)QLEDGDQPESK(K) 
(R)TSMTEEYRVPDGMVGLIIGR(G) 
1,532.80 
2,309.10 
1,183.72 
1,244.58 
2,255.11 
2 
3 
2 
2 
3 
 
0.0053 
-0.0075 
0.0258 
0.0233 
0.0123 
43.5492 
42.4608 
43.3738 
43.9370 
42.5643 
 
Fumarate hydratase, FH P07954 6 54638 9.1 23 ↑ CPA, 
OHF 
(R)AIEMLGGELGSK(I) 
(R)IEYDTFGELKVPNDKYYGAQTVR(S) 
(K)IPVHPNDHVNK(S) 
(R)IYELAAGGTAVGTGLNTR(I) 
(K)SQSSNDTFPTAMHIAAAIEVHEVLLPGLQK(L) 
(R)THTQDAVPLTLGQEFSGYVQQVK(Y) 
 
1,219.62 
2,705.34 
1,268.69 
1,762.91 
3,219.60 
2,545.26 
2 
4 
3 
2 
4 
3 
0.0098 
0.0077 
0.0314 
-0.0131 
-0.0252 
-0.0185 
43.7994 
41.9537 
43.5480 
43.3331 
41.0147 
42.2817 
 
Bifunctional purine biosynthesis 
protein, PURH 
P31939 4 64617 6.6 10 ↓CPA, 
OHF 
(M)APGQLALFSVSDK(T) 
(M)APGQLALFSVSDKTGLVEFAR(N) 
(K)NGQVIGIGAGQQSR(I) 
(K)TVASPGVTVEEAVEQIDIGGVTLLR(A) 
 
1,331.72 
2,205.19 
1,383.72 
2,552.37 
2 
3 
2 
3 
0.0072 
0.0140 
0.0008 
-0.0045 
43.9252 
42.7224 
43.7900 
42.0801 
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RNA binding protein (isoform 2),  
DJ-1  
Q99497 1* 19891 6.7 14 ↓ 
OHF,CPA 
 
 
(R)GPGTSFEFALAIVEALNGKEVAAQVK(A)  2645.40 3 -0.0081 41.8983 
 
 
Glyoxalase domain-containing protein 
4, GLOD4 
Q9HC38 5 34794 5.4 26 ↓ OHF 
>↓CPA 
(K)GGVDHAAAFGR(I) 
(K)ILTPLVSLDTPGK(A) 
(K)LGNDFMGITLASSQAVSNAR(K) 
(K)TMVGFGPEDDHFVAELTYNYGVGDYK(L) 
(K)VTLAVSDLQK(S) 
1,056.43 
1,352.80 
2,066.97 
2,939.32 
1,072.62 
2 
2 
2 
3 
2 
-0.0767 
0.0094 
-0.0345 
0.0201 
0.0087 
44.9969 
35.0961 
42.8228 
33.1869 
36.4748 
 
Regulation in common between 
mibolerone and antiandrogen 
            
Glutamate dehydrogenase 1, GLUD1 P00367 4 61379 8.0 15 ↑ MIB, 
CPA, OHF 
(R)DSNYHLLMSVQESLER(K) 
(K)ELEDFKLQHGSILGFPK(A) 
(K)GFIGPGIDVPAPDMSTGER(E) 
(R)YSTDVSVDEVK(A) 
 
1,935.93 
1,957.05 
1,930.90 
1,240.60 
 
3 
3 
2 
2 
0.0295 
0.0203 
-0.0122 
0.0183 
42.8738 
42.9447 
43.1061 
43.6324 
Up with 
androgen 
(24)  
Catalase, CAT P04040 2 59757 7.4 8 ↑ 
MIB,CPA 
(K)ADVLTTGAGNPVGDKLNVITVGPR(G) 
(R)FSTVAGESGSADTVRDPR(G) 
 
2,363.27 
1,850.89 
3 
3 
-0.0087 
0.0152 
42.3940 
43.0490 
 
Elongation factor 2, EEF2 P13639 9 95340 6.9 20 ↑ 
BIC>↑MIB, 
CPA, OHF 
(R)ALLELQLEPEELYQTFQR(I) 
(K)ARPFPDGLAEDIDKGEVSAR(Q) 
(K)AYLPVNESFGFTADLR(S) 
(K)DGAGFLINLIDSPGHVDFSSEVTAALR(V) 
(K)EGIPALDNFLDKL(-) 
(R)NMSVIAHVDHGK(S) 
(K)STAISLFYELSENDLNFIK(Q) 
(R)VFSGLVSTGLK(V) 
(R)WLPAGDALLQMITIHLPSPVTAQK(Y) 
 
2,218.96 
2,142.07 
1,798.91 
2,800.22 
1,443.77 
1,322.69 
2,203.10 
1,106.66 
2,615.42 
 
3 
3 
2 
3 
2 
3 
2 
2 
3 
 
-0.1895 
0.0033 
0.0242 
-0.1872 
0.0104 
0.0479 
-0.0079 
0.0214 
0.0091 
 
43.8637 
42.6392 
35.0065 
43.6065 
43.6075 
35.3428 
34.4948 
43.7057 
33.9005 
Up with 
androgen 
(11, 24, 32)  
 
Multifunctional protein ADE2, 
PAICS 
P22234 2 47080 7.4 11 ↑ 
CPA,MIB 
(R)IKAEYEGDGIPTVFVAVAGR(S) 
(K)TKEVYELLDSPGK(V)  
1,046.56 
739.89 
2 
2 
0.0040 
0.0056 
 
42.8197 
43.4142 
 
Triosephosphate isomerise, TPIS P60174 5 30791 6.9 27 ↑ CPA, 
OHF 
>↑MIB 
(R)HVFGESDELIGQK(V) 
(K)QSLGELIGTLNAAK(V) 
(K)SNVSDAVAQSTR(I) 
(K)TATPQQAQEVHEK(L) 
(K)VTNGAFTGEISPGMIK(D) 
 
1,457.75 
1,413.78 
1,233.61 
1,465.72 
1,636.79 
3 
2 
2 
2 
2 
0.0319 
-0.0051 
0.0182 
0.0004 
-0.0206 
43.7497 
43.6821 
43.6687 
43.2650 
43.2389 
Up with 
androgen 
(24)  
X-ray repair cross-complementing 
protein 5, XRCC5 
P13010 2 82707 5.6 5 ↓ 
BIC>↓MIB 
(R)DDEAAAVALSSLIHALDDLDMVAIVR(Y) 
(K)EEASGSSVTAEEAK(K) 
2,738.37 
1,393.64 
3 
2 
-0.0102 
0.0240 
 
41.8361 
43.3201 
Down with 
androgen 
(11, 32) 
Peroxidoredoxin 2, PRDX2 P32119 6 21892 5.9 35 ↓ BIC,MIB, 
OHF 
(K)EGGLGPLNIPLLADVTR(R) 
(R)KEGGLGPLNIPLLADVTR(R) 
(K)LGCEVLGVSVDSQFTHLAWINTPR(K) 
(R)LSEDYGVLKTDEGIAYR(G) 
(R)QITVNDLPVGR(S) 
(K)TDEGIAYR(G) 
 
1,733.93 
1,862.05 
2,698.29 
1,927.97 
1,210.66 
923.44 
2 
2 
3 
3 
2 
2 
-0.0349 
-0.0169 
-0.0627 
0.0127 
-0.0055 
0.0083 
43.2539 
43.0449 
42.3009 
43.0081 
43.3476 
42.4983 
 
Serine hydroxymethyltransferase, P34897 4 55995 8.8 11 ↓ MIB,BIC  (R)AMADALLER(G) 1,004.53 2 0.0345 44.3892  
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SHMT2 (R)ISATSIFFESMPYK(L) 
(K)TGLIDYNQLALTAR(L) 
(R)VVDFIDEGVNIGLEVK(S) 
1,635.78 
1,547.83 
1,744.92 
2 
2 
2 
-0.0060 
-0.0045 
-0.0001 
43.1923 
43.5249 
43.4153 
             
Regulation in opposition             
Splicing factor 35kDA subunit, 
U2AF1 
Q01081 2 27872 9.1 11 ↑CPA, ↓ 
OHF 
(M)AEYLASIFGTEKDK(V) 
(R)NPQNSSQSADGLR(C) 
1,612.79 
1,372.65 
2 
2 
 
-0.0128 
0.0187 
  
43.9884 
 
Creatine kinase B-type, CKB P12277 7 42645 5.5 23 ↑MIB, 
↓BIC 
(K)GGNMKEVFTR(F) 
(R)GTGGVDTAAVGGVFDVSNADR(L) 
(K)LAVEALSSLDGDLAGR(Y) 
(R)LEQGQAIDDLMPAQK(-) 
(R)LGFSEVELVQMVVDGVK(L) 
(R)LGFSEVELVQMVVDGVKLLIEMEQR(L) 
(K)LLIEMEQR(L) 
 
1,153.58 
1,963.93 
1,585.86 
1,671.78 
1,863.99 
2,892.49 
1,046.54 
2 
2 
2 
2 
2 
3 
2 
0.0286 
0.0065 
0.0277 
-0.0353 
0.0247 
-0.0050 
-0.0055 
43.3005 
42.7353 
43.6743 
43.3532 
43.0735 
41.6557 
44.2711 
Up with 
androgen 
(11)  
Pyruvate kinase, isozymes M1/M2, 
PKM 
P14618 6 57938 8.2 16 ↑MIB, ↓ 
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